Drug Approval | June 23, 2022
Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
Both manufacturing facilities are based out of Benguluru, India
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Subscribe To Our Newsletter & Stay Updated
